肺炎鏈球菌疫苗市場：按疫苗類型（肺炎鏈球菌結合疫苗、肺炎鏈球菌多醣體疫苗）、目標人口、按給藥途徑、按分銷管道、按地區

預計2024年全球肺炎鏈球菌疫苗市場規模為89.2億美元，預計2031年將達到125.1億美元，2024年至2031年複合年成長率為4.9%。

圖：2024 年按地區分類的肺炎鏈球菌疫苗市場佔有率(%)

全球肺炎球菌疫苗市場的成長是由全球肺炎球菌疾病盛行率上升和政府加強免疫計劃等因素所推動的。此外，人們對肺炎球菌疫苗接種的認知不斷提高也推動了市場的成長。然而，肺炎球菌疫苗開發和生產的高成本可能會阻礙市場成長。持續研究和開發負擔得起且有效的疫苗可能會在不久的將來提供新的機會。

市場動態：

全球肺炎鏈球菌疫苗市場的成長主要是由全球肺炎球菌肺炎、腦膜炎和其他嚴重感染疾病盛行率上升所推動的。據世界衛生組織(WHO)稱，肺炎是5歲以下兒童死亡的前五位原因之一。此外，增加政府資金和透過國家免疫計劃促進免疫計劃的舉措可能會推動市場成長。然而，肺炎鏈球菌疫苗高昂的研發和製造成本可能會阻礙市場擴張。正在進行的評估新型多效價肺炎鏈球菌製劑的安全性和有效性的臨床試驗可能會推動市場成長。新興國家擁有發達的醫療基礎設施，為市場進入者提供了巨大的機會。

本研究的主要特點

本報告對全球肺炎球菌疫苗市場進行了詳細分析，並列出了以2023年為基準年的預測期（2024-2031年）的市場規模和年均成長率。

它還揭示了各個細分市場的潛在商機，並解釋了該市場中有吸引力的投資提案的矩陣。

它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的主要考察。

根據公司亮點、產品系列、主要亮點、績效和策略等參數，包括全球肺炎鏈球菌疫苗市場的主要企業概況。

主要公司包括輝瑞公司、默克公司、葛蘭素史克公司和賽諾菲公司。

本報告中的見解將幫助負責人和公司經營團隊就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。

全球肺炎球菌疫苗市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。

目錄

第1章 研究目的與前提

• 研究目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要

第3章 市場動態、法規與趨勢分析

• 市場動態
• 影響分析
• 主要亮點
• 監管場景
• 產品發布/核准
• PEST分析
• 波特分析
• 併購場景

第4章全球肺炎鏈球菌疫苗市場，依疫苗類型，2019-2031

• 肺炎鏈球菌結合疫苗 (PCV)
• 肺炎鏈球菌多醣體疫苗（PPV）

第5章全球肺炎鏈球菌疫苗市場，依目標人口，2019-2031

• 成人（65歲以上）
• 兒童（5歲以下）
• 高危險群成人（18-64 歲）

第6章 全球肺炎鏈球菌疫苗市場，依給藥途徑，2019-2031 年

• 肌肉注射
• 皮下的

第7章全球肺炎鏈球菌疫苗市場，依通路，2019-2031

• 醫院藥房
• 零售藥房
• 網路藥房

第8章全球肺炎鏈球菌疫苗市場，按地區，2019-2031

• 拉丁美洲
• 歐洲
• 亞太地區
• 中東

第9章 競爭格局

• Pfizer Inc.
• Merck & Co., Inc.
• GlaxoSmithKline plc（GSK）
• Sanofi
• CSL Limited
• Serum Institute of India Pvt. Ltd.
• Vaxcyte, Inc.
• Astellas Pharma Inc.
• Panacea Biotec Ltd.
• Walvax Biotechnology Co., Ltd.
• Beijing Minhai Biotechnology Co., Ltd.
• Merck KGaA
• Takeda Pharmaceutical Company Limited
• AbbVie Inc.
• Novartis AG
• Johnson & Johnson
• Biovac
• Bharat Biotech
• Inovio Pharmaceuticals, Inc.
• Hilleman Laboratories Pvt. Ltd

第10章分析師建議

• 命運之輪
• 分析師觀點
• 一致的機會圖

第11章 參考文獻與調查方法

• 參考
• 調查方法
• 關於出版商

Global pneumococcal vaccines market is estimated to be valued at USD 8.92 billion in 2024 and is expected to reach USD 12.51 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031.

Figure. Pneumococcal Vaccines Market Share (%), By Region 2024

Global pneumococcal vaccines market growth is driven by factors such as rising incidence of pneumococcal diseases worldwide and growing immunization programs by various governments. Moreover, increasing awareness among people regarding pneumococcal vaccination can also drive the market growth. However, high costs associated with pneumococcal vaccines development and production can hamper the market growth. Ongoing research activities for developing affordable and effective vaccines can offer new opportunities in the near future.

Market Dynamics:

Global pneumococcal vaccines market growth is primarily driven by rising prevalence of pneumococcal pneumonia, meningitis, and other serious infections caused by Streptococcus pneumoniae bacteria worldwide. As per the World Health Organization (WHO), pneumonia is one of the top five causes of death in children under age of 5 years. Moreover, increasing government funding and initiatives to promote immunization programs through national immunization schedules can drive the market growth. However, high research, development and production costs of pneumococcal vaccines can hamper the market expansion. Ongoing clinical trials assessing the safety and efficacy of new multivalent pneumococcal formulations can drive the market growth. Emerging economies present significant opportunities for market players owing to improving healthcare infrastructures in these countries.

Key features of the study:

This report provides in-depth analysis of the global pneumococcal vaccines market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global pneumococcal vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., Merck & Co., GSK plc., and Sanofi

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global pneumococcal vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Detailed Segmentation-

• By Vaccine Type
  • Pneumococcal Conjugate Vaccines (PCVs)
  • PCV13 (Prevnar 13/Prevenar 13)
  • PCV10 (Synflorix)
  • PCV7 (Prevnar/Prevenar)
  • Pneumococcal Polysaccharide Vaccines (PPVs)
  • PPSV23 (Pneumovax 23)
  • PPSV14 (Pneumo 14)
• By Target Population
  • Adults (>= 65 years)
  • Children (< 5 years)
  • High-Risk Adults (18-64 years)
• By Route of Administration
  • Intramuscular
  • Subcutaneous
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
• Key Players Insights
  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc (GSK)
  • Sanofi
  • CSL Limited
  • Serum Institute of India Pvt. Ltd.
  • Vaxcyte, Inc.
  • Astellas Pharma Inc.
  • Panacea Biotec Ltd.
  • Walvax Biotechnology Co., Ltd.
  • Beijing Minhai Biotechnology Co., Ltd.
  • Merck KGaA
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.
  • Novartis AG
  • Johnson & Johnson
  • Biovac
  • Bharat Biotech
  • Inovio Pharmaceuticals, Inc.
  • Hilleman Laboratories Pvt. Ltd

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Pneumococcal Vaccines Market, By Vaccine Type
  • Global Pneumococcal Vaccines Market, By Target Population
  • Global Pneumococcal Vaccines Market, By Route of Administration
  • Global Pneumococcal Vaccines Market, By Distribution Channel
  • Global Pneumococcal Vaccines Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Pneumococcal Vaccines Market, By Vaccine Type, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Pneumococcal Conjugate Vaccines (PCVs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • PCV13 (Prevnar 13/Prevenar 13)
  • PCV10 (Synflorix)
  • PCV7 (Prevnar/Prevenar)
• Pneumococcal Polysaccharide Vaccines (PPVs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • PPSV23 (Pneumovax 23)
  • PPSV14 (Pneumo 14)

5. Global Pneumococcal Vaccines Market, By Target Population, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Adults (>= 65 years)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Children (< 5 years)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• High-Risk Adults (18-64 years)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Pneumococcal Vaccines Market, By Route of Administration, 2019-2031, (USD Bn)

• Intramuscular
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Subcutaneous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Pneumococcal Vaccines Market, By Distribution Channel, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Pneumococcal Vaccines Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2024,2027 & 2031, (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2020- 2031, (USD Bn)
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Target Population, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Target Population, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Target Population, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Target Population, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Target Population, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, By Vaccine Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Target Population, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, By Country/Sub-region, 2019 - 2031, (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline plc (GSK)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• CSL Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Serum Institute of India Pvt. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Vaxcyte, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Astellas Pharma Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Panacea Biotec Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Walvax Biotechnology Co., Ltd.
• Beijing Minhai Biotechnology Co., Ltd.
• Merck KGaA
• Takeda Pharmaceutical Company Limited
• AbbVie Inc.
• Novartis AG
• Johnson & Johnson
• Biovac
• Bharat Biotech
• Inovio Pharmaceuticals, Inc.
• Hilleman Laboratories Pvt. Ltd

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us